IRulya Therapeutics Inc. (IRLA) Stock AnalysisIRLAIRulya Therapeutics Inc.

IRulya Therapeutics, Inc., formerly Quince Therapeutics, Inc., is a clinical-stage biopharmaceutical company. It is developing a novel disease-modifying therapeutic to address the unmet medical need associated with pulmonary disorders. Its lead asset, LAM-001, a proprietary investigational inhaled dry powder formulation of rapamycin whose differentiated characteristics may permit treatment of pulmonary conditions associated with dysfunctional mammalian target of rapamycin activity. It is evaluating the use of LAM-001 as a treatment for patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) and for patients with bronchiolitis obliterans syndrome post lung transplant (BOS). It also completed a Phase 2a trial, which enrolled patients with pulmonary arterial hypertension as well as patients with PH-ILD and sarcoidosis associated pulmonary hypertension (SAPH) where it achieved clinically relevant improvement across multiple endpoints, and others.

IRulya Therapeutics Inc is currently trading at $33.55, which is 53.1% of its 52-week range. The stock has shown a positive 5-day change of +6.92% and a year-to-date change of +5.74%. However, the upcoming earnings report on November 11, 2026, has an estimated EPS of -0.83, indicating potential volatility. The stock's performance is also against a backdrop of a declining market, with the SPY down 1.73% over the last 5 days. Given these factors, it may be prudent to hold rather than buy at this time.